Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.52 |
| ▸ | PKM | P14618 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747239 | 1.00 | MAPT (0.52) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL17071336 | 0.89 | MAPT (0.56) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1700879 | 0.87 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1700440 | 0.87 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL16160645 | 0.87 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1700443 | 0.87 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1700499 | 0.85 | MAPT (0.53) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL1700911 | 0.84 | MAPT (0.51) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL21542144 | 0.84 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL523824 | 0.84 | MAPT (0.55) | MAPTPKMPOLBSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | MAPT 2900/4885PKM 4250/4885POLB 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.